SHAREHOLDERS AGREEMENT DATED AS OF OCTOBER 17, 2018 AMONG OSMOTICA PHARMACEUTICALS PLC ACP HOLDCO (OFFSHORE), L.P. ACP III AIV, L.P. ALTCHEM LIMITED ORBIT CO-INVEST A-I LLC ORBIT CO-INVEST 1 LLC ORBIT CO-INVEST II LLC ORBIT CO-INVEST III LLC AND THE...Shareholders Agreement • January 23rd, 2020 • Avista Capital Partners III GP, L.P. • Pharmaceutical preparations • New York
THIS SHAREHOLDERS AGREEMENT (this “Agreement”), dated as of October 17, 2018, is entered into by and among Osmotica Pharmaceuticals plc, a public limited company incorporated under the laws of Ireland with registration number 607944 and registered office at 25-28 North Wall Quay, Dublin 1, Ireland (together with its successors, the “Company”), ACP Holdco (Offshore), L.P., a Bermuda exempted limited partnership (“ACP Offshore”), ACP III AIV, L.P., a Bermuda exempted limited partnership (the “VCOC”, and together with ACP Offshore, the “Avista Shareholder”), Altchem Limited (the “Altchem Shareholder”), and each of Altchem, on the one hand, and the Avista Shareholder, collectively, on the other hand, a “Sponsor”), Orbit Co-Invest A-I LLC, a Delaware LLC (“Orbit A-1”), Orbit Co-Invest I LLC, a Delaware LLC (“Orbit 1”) and Orbit Co-Invest III, LLC (“Orbit 3”, and together with Orbit A-1 and Orbit 1, the “Co-Invest Vehicles”), the shareholders listed on Annex A hereto as Management Shareholde
JOINT FILING AGREEMENTJoint Filing Agreement • November 23rd, 2020 • Avista Capital Partners III GP, L.P. • Pharmaceutical preparations
This Joint Filing Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.
AGREEMENT AS TO JOINT FILING OF SCHEDULE 13GAvista Capital Partners III GP, L.P. • February 7th, 2019 • Pharmaceutical preparations
The undersigned hereby agree that the Schedule 13G relating to the ordinary shares of Osmotica Pharmaceuticals plc, and any further amendments thereto, to which this Agreement as to Joint Filing of Schedule 13G is attached as an exhibit is filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
LETTER AGREEMENTLetter Agreement • November 23rd, 2020 • Avista Capital Partners III GP, L.P. • Pharmaceutical preparations • Delaware
This LETTER AGREEMENT (this “Agreement”) is entered into on November 19, 2020, by and among Avista Capital Partners III GP, L.P. (“Avista”), Osmotica Pharmaceuticals plc (“Osmotica”), Orbit Co-Invest I, LLC (“Orbit I”), SDK VC Pharma Holding Corp. (“SDK”), and Steven Squashic, Kevin Hudy and David Purdy (collectively, the “SDK Shareholders” and, together with SDK, the “SDK Parties”, and together with Avista and Osmotica, the “Parties”)).
JOINT FILING AGREEMENTJoint Filing Agreement • January 23rd, 2020 • Avista Capital Partners III GP, L.P. • Pharmaceutical preparations
This Joint Filing Agreement may be executed in separate counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.
